Transitioning from discovery to clinical development marks a defining moment for emerging biotech companies. It’s also a time to consider evolving your IP strategy from protecting ideas to protecting assets.
Why Does IP Become Critical at IND?
When filing an investigational new drug (IND) application, sponsors disclose detailed chemistry, manufacturing, and control (CMC) information, and those disclosures may reveal trade secrets or impact the ability to extend patent exclusivity. If the IP framework hasn’t been fortified before this point, competitors may quickly identify design-around strategies or exploit weak patent claims.
Key Considerations for a Clinical-Ready IP Strategy
- Review composition claims: Ensure core product and analogs are covered by strong, enabled claims with appropriate genus and species scope.
- Secure method-of-use coverage: Protect clinical indications, formulations, dosing regimens, and administration routes that will be disclosed in the IND or trial design.
- Align regulatory and patent timelines: Coordinate patent prosecution and publication with clinical milestones to preserve exclusivity and avoid premature disclosure.
- Lock down manufacturing know-how: Protect CMC information by ensuring contracts, vendors, and data-sharing protocols safeguard confidentiality.
- Evaluate freedom-to-operate (FTO): Revisit FTO analyses to account for new filings and potential blocking patents.
How to Avoid the ‘Data Disclosure Trap’
Regulators require transparency, but disclosure doesn’t have to erode competitive advantage. Working with patent counsel early can help structure filings, publications, and regulatory submissions to maximize protection, so that by the time you go clinical, your IP position remains both strong and defensible.
Bottom Line
Clinical readiness includes both the science and the strategy that surrounds it. A proactive IP approach helps ensure that the data you generate drives value for your company, not opportunities for competitors.
[View source.]
